Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Syst Biol Reprod Med ; 68(4): 247-257, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35481403

ABSTRACT

"Differences of Sexual Development (DSD)," individuals with rearranged Y chromosome breaks in their 46,XY cells are reported with male and female gender phenotypes and differences in germ cell tumour (GCT) risk. This raised the question of whether male or female gender and GCT risk depends on the site of the break and/or rearrangement of the individual´s Y chromosome. In this paper, we report molecular mapping of the breakpoint on the aberrant Y chromosome of 22 DSD individuals with a 45,X/46,XY karyotype reared with a different gender. Their Y chromosome breaks are found at different sites on the long and short Y arms. Our data indicate that gender rearing is, neither dependent on the site of Y breakage, nor on the amount of 45,X0 cells in the individuals' leukocytes. Most prominent are secondary rearrangements of the Y chromosome breaks forming di-centric Y-structures ("dic-Y"). Duplications of the short Y arm and the proximal part of the long Y arm are the results. A putative GCT risk has been analysed with immunohistochemical experiments on some dysgenetic gonadal tissue sections. With specific antibodies for OCT3/4 expression, we marked the pluripotent germ cell fraction being potential tumour precursor cells. With specific antibodies for DDX3Y, TSPY, and UTY we analyzed their putative Gonadoblastoma Y (GBY) tumour susceptibility function in the same specimen. We conclude GBY expression is only diagnostic for GCT development in the aberrant germ cells of these DSD individuals when strong OCT3/4 expression has marked their pluripotency.


Subject(s)
Gonadoblastoma , Neoplasms, Germ Cell and Embryonal , Ovarian Neoplasms , Sex Chromosome Disorders of Sex Development , Chromosome Breakage , Chromosomes, Human, Y/metabolism , DEAD-box RNA Helicases/genetics , Female , Gonadoblastoma/genetics , Gonadoblastoma/metabolism , Gonadoblastoma/pathology , Humans , Male , Minor Histocompatibility Antigens , Ovarian Neoplasms/genetics , Phenotype
2.
PLoS One ; 7(5): e38220, 2012.
Article in English | MEDLINE | ID: mdl-22693602

ABSTRACT

Intrauterine and postnatal longitudinal growth is controlled by a strong genetic component that regulates a complex network of endocrine factors integrating them with cellular proliferation, differentiation and apoptotic processes in target tissues, particularly the growth centers of the long bones. Here we report on a patient born small for gestational age (SGA) with severe, proportionate postnatal growth retardation, discreet signs of skeletal dysplasia, microcephaly and moyamoya disease. Initial genetic evaluation revealed a novel heterozygous IGF1R p.Leu1361Arg mutation affecting a highly conserved residue with the insulin-like growth factor type 1 receptor suggestive for a disturbance within the somatotropic axis. However, because the mutation did not co-segregate with the phenotype and functional characterization did not reveal an obvious impairment of the ligand depending major IGF1R signaling capabilities a second-site mutation was assumed. Mutational screening of components of the somatotropic axis, constituents of the IGF signaling system and factors involved in cellular proliferation, which are described or suggested to provoke syndromic dwarfism phenotypes, was performed. Two compound heterozygous PCNT mutations (p.[Arg585X];[Glu1774X]) were identified leading to the specification of the diagnosis to MOPD II. These investigations underline the need for careful assessment of all available information to derive a firm diagnosis from a sequence aberration.


Subject(s)
Antigens/genetics , Heterozygote , Mutation , Phenotype , Receptor, IGF Type 1/genetics , Adolescent , Bone and Bones/diagnostic imaging , Child , Child, Preschool , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Humans , Infant , Infant, Newborn , Mitogen-Activated Protein Kinases/metabolism , Neuroimaging , Phosphorylation , Proto-Oncogene Proteins c-akt/metabolism , Radiography
3.
Clin Endocrinol (Oxf) ; 75(6): 760-5, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21645025

ABSTRACT

OBJECTIVE: Autosomal dominant hypocalcaemia or hypoparathyroidism is caused by activating mutations of the calcium-sensing receptor (CaSR). Treatment with calcium and vitamin D often worsens hypercalciuria and nephrocalcinosis, and renal impairment can result. Our aim was to describe the phenotypic variance of this rare disorder in a large series and to evaluate the outcome after long-term treatment. DESIGN: Nationwide retrospective collaborative study. PATIENTS: We describe 25 patients (14 men and 11 women), 20 belonging to 11 families and five single cases. MEASUREMENTS: Activating CaSR mutations and clinical and biochemical findings were evaluated. RESULTS: Nine different missense mutations of the CaSR, including one novel variant (M734T), were found. Twelve patients (50%) were symptomatic, 9 (36%) had basal ganglia calcifications and 3 (12%) had nephrocalcinosis. Serum calcium was decreased (1·87 ± 0·13 mm), and PTH was decreased (n = 19) or inappropriately low (n = 4). The occurrence of hypocalcaemic symptoms at diagnosis was related to the degree of hypocalcaemia. The occurrence of features like calcification of basal ganglia or kidney calcification did not correlate with the severity of hypocalcaemia or the age at diagnosis. The most common treatment was calcitriol (median dosage 0·6 µg/day), and the mean duration of therapy was 7·1 years (max. 26 years). Hypercalcaemic episodes rarely occurred, and the rate of kidney calcifications was remarkably low (12%). CONCLUSION: This series increases the limited knowledge of mutations and phenotypes of this rare disorder. Mutation analysis of the CaSR gene facilitates patient and family management. Low dosages of calcitriol resulted in less frequent renal calcifications.


Subject(s)
Hypocalcemia/genetics , Mutation , Receptors, Calcium-Sensing/genetics , Adolescent , Adult , Child , Child, Preschool , Cohort Studies , DNA Mutational Analysis , Data Collection , Female , Genes, Dominant , Germany/epidemiology , Humans , Hypocalcemia/epidemiology , Infant , Infant, Newborn , Male , Middle Aged , Mutation/physiology , Phenotype , Receptors, Calcium-Sensing/chemistry , Retrospective Studies , Young Adult
4.
J Allergy Clin Immunol ; 122(6): 1105-1112.e1, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18951619

ABSTRACT

BACKGROUND: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is an autoimmune genetic disorder caused by mutation of the forkhead box protein 3 gene (FOXP3), a key regulator of immune tolerance. OBJECTIVE: We sought to provide clinical and molecular indicators that facilitate the understanding and diagnosis of IPEX syndrome. METHODS: In 14 unrelated affected male subjects who were given diagnoses of IPEX syndrome based on FOXP3 gene sequencing, we determined whether particular FOXP3 mutations affected FOXP3 protein expression and correlated the molecular and clinical data. RESULTS: Molecular analysis of FOXP3 in the 14 subjects revealed 13 missense and splice-site mutations, including 7 novel mutations. Enteropathy, generally associated with endocrinopathy and eczema, was reported in all patients, particularly in those carrying mutations within FOXP3 functional domains or mutations that altered protein expression. However, similar genotypes did not always result in similar phenotypes in terms of disease presentation and severity. In addition, FOXP3 protein expression did not correlate with disease severity. CONCLUSION: Severe autoimmune enteropathy, which is often associated with increased IgE levels and eosinophilia, is the most prominent early manifestation of IPEX syndrome. Nevertheless, the disease course is variable and somewhat unpredictable. Therefore genetic analysis of FOXP3 should always be performed to ensure an accurate diagnosis, and FOXP3 protein expression analysis should not be the only diagnostic tool for IPEX syndrome.


Subject(s)
Forkhead Transcription Factors/genetics , Gene Expression Regulation/genetics , Genetic Diseases, X-Linked/genetics , Immunologic Deficiency Syndromes/genetics , Intestinal Diseases/genetics , Mutation , Polyendocrinopathies, Autoimmune/genetics , DNA Mutational Analysis/methods , Forkhead Transcription Factors/immunology , Gene Expression Regulation/immunology , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/immunology , Genetic Diseases, X-Linked/therapy , Genotype , Humans , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/immunology , Immunologic Deficiency Syndromes/therapy , Intestinal Diseases/diagnosis , Intestinal Diseases/immunology , Intestinal Diseases/therapy , Male , Mutation/immunology , Phenotype , Polyendocrinopathies, Autoimmune/diagnosis , Polyendocrinopathies, Autoimmune/immunology , Polyendocrinopathies, Autoimmune/therapy , Protein Structure, Tertiary/genetics , Syndrome
5.
Hum Mutat ; 29(1): 59-64, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17694559

ABSTRACT

Steroidogenic factor 1 (SF1, NR5A1) is a nuclear receptor that regulates multiple genes involved in adrenal and gonadal development, steroidogenesis, and the reproductive axis. Human mutations in SF1 were initially found in two 46,XY female patients with severe gonadal dysgenesis and primary adrenal failure. However, more recent case reports have suggested that heterozygous mutations in SF1 may also be found in patients with 46,XY partial gonadal dysgenesis and underandrogenization but normal adrenal function. We have analyzed the gene encoding SF1 (NR5A1) in a cohort of 27 patients with 46,XY disorders of sex development (DSD) from the German network of DSD. Heterozygous SF1 mutations were found in 5 out of 27 (18.5%) of cases. Four patients with SF1 mutations presented with the similar phenotype of mild gonadal dysgenesis, severe underandrogenization, and absent Müllerian structures. Of these, two patients harbored missense mutations within the DNA-binding region of SF1 (p.C33S, p.R84H), one patient had a nonsense mutation (p.Y138X) and one patient had a frameshift mutation (c.1277dupT) predicted to disrupt RNA stability or protein function. One additional patient ([c.424_427dupCCCA]+[p.G146A]) displayed a more marked phenotype of severe gonadal dysgenesis, normal female external genitalia, and Müllerian structures. Functional studies of the missense mutants (p.C33S, p.R84H) and of one nonsense mutant (p.Y138X) revealed impaired transcriptional activation of SF1-responsive target genes. To date, adrenal insufficiency has not occurred in any of the patients. Thus, SF1 mutations are a relatively frequent cause of 46,XY DSD in humans.


Subject(s)
Gonadal Dysgenesis, 46,XY/genetics , Mutation , Steroidogenic Factor 1/genetics , Adolescent , Adrenal Glands/metabolism , Adrenal Insufficiency/diagnosis , Adult , Child , Child, Preschool , Cohort Studies , Female , Gonadal Dysgenesis, 46,XY/diagnosis , Humans , Steroidogenic Factor 1/analysis
6.
Horm Res ; 62(2): 84-7, 2004.
Article in English | MEDLINE | ID: mdl-15249739

ABSTRACT

We report the observation and analysis of a new adverse event during the insulin tolerance test (ITT) and propose additional safety procedures. An 8-year-old girl with growth hormone insufficiency had a cardiac arrest due to ventricular flutter when she was tested for growth hormone deficiency by the ITT. Severe hypokalaemia (K+ 2.6 mmol/l) was observed after resuscitation. Ergometry ECG revealed catecholaminergic polymorphic ventricular tachycardia, a hereditary arrhythmogenic disease. Consecutive measurements of serum potassium during ITT in 29 short children (21 boys) with growth failure revealed a mean decrease of serum potassium by 1.1 +/- 0.4 mmol/l with the nadir at 30 min after the insulin bolus. Hypokalaemia (serum potassium < 3.5 mmol/l) occurred in all but one child; severe hypokalaemia (serum potassium < 2.9 mmol/l) was measured in every third child. This observation indicates that acute hypokalaemia which is induced by insulin and catecholamine excess occurs frequently in ITT. The case shows that the combination of acute hypokalaemia and the adrenergic counterregulation in ITT is a strong trigger of cardiac arrhythmias, which can become life-threatening if the child has an arrhythmogenic disease. Therefore, we recommend ECG monitoring during ITT to enhance the detection of cardiac arrhythmias. In addition, in the case of a comatose child during ITT the determination of the glucose and potassium level as well as adequate treatment are necessary.


Subject(s)
Arrhythmias, Cardiac/chemically induced , Diagnostic Tests, Routine/adverse effects , Dwarfism, Pituitary/diagnosis , Hypokalemia/chemically induced , Insulin , Adolescent , Arrhythmias, Cardiac/diagnosis , Blood Glucose , Child , Child, Preschool , Female , Humans , Insulin/adverse effects , Male
7.
Eur J Pediatr ; 163(7): 347-52, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15107988

ABSTRACT

UNLABELLED: Mutations in the human sonic hedgehog gene (SHH) are the most frequent cause of autosomal dominant inherited holoprosencephaly (HPE), a complex brain malformation resulting from incomplete cleavage of the developing forebrain into two separate hemispheres and ventricles. Here we report the clinical and molecular findings in five unrelated patients with HPE and their relatives with an identified SHH mutation. Three new and one previously reported SHH mutations were identified, a fifth proband was found to carry a reciprocal subtelomeric rearrangement involving the SHH locus in 7q36. An extremely wide intrafamilial phenotypic variability was observed, ranging from the classical phenotype with alobar HPE accompanied by typical severe craniofacial abnormalities to very mild clinical signs of choanal stenosis or solitary median maxillary central incisor (SMMCI) only. Two families were initially ascertained because of microcephaly in combination with developmental delay and/or mental retardation and SMMCI, the latter being a frequent finding in patients with an identified SHH mutation. In other affected family members a delay in speech acquisition and learning disabilities were the leading clinical signs. CONCLUSION: mutational analysis of the sonic hedgehog gene should not only be considered in patients presenting with the classical holoprosencephaly phenotype but also in those with two or more clinical signs of the wide phenotypic spectrum of associated abnormalities, especially in combination with a positive family history.


Subject(s)
Holoprosencephaly/genetics , Trans-Activators/genetics , Adult , Base Sequence , DNA Mutational Analysis , Female , Hedgehog Proteins , Humans , In Situ Hybridization, Fluorescence , Infant, Newborn , Male , Mutation , Pedigree , Phenotype , Polymerase Chain Reaction
8.
Cancer Lett ; 196(1): 23-7, 2003 Jun 30.
Article in English | MEDLINE | ID: mdl-12860285

ABSTRACT

In humans and gene-targeted mice, loss of multiple endocrine neoplasia type 1 (MEN1) tumor suppressor gene function causes neuroendocrine tumors, frequently of the parathyroid and pituitary glands and the pancreas. The MEN1 gene product interacts with glial fibrillary acidic protein (GFAP) in the brain. We here demonstrate bi-allelic MEN1 inactivation in a grade II astrocytoma in an individual carrying a heterozygous MEN1 germ line deletion mutation (788del6). This tumor represents a novel, non-endocrine MEN1-phenotype, compatible with a role of MEN1-GFAP in glial oncogenesis. Clinically, a genetic predisposition to variant neoplasias should be considered in the management of MEN1 patients.


Subject(s)
Astrocytoma/genetics , Brain Neoplasms/genetics , Genes, Tumor Suppressor , Loss of Heterozygosity , Neoplasm Proteins/genetics , Proto-Oncogene Proteins , Base Sequence , Child , Germ-Line Mutation , Humans , Male , Multiple Endocrine Neoplasia Type 1/complications
9.
J Clin Invest ; 109(6): 725-33, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11901181

ABSTRACT

Deficiency of the Golgi enzyme UDP-Gal:N-acetylglucosamine beta-1,4-galactosyltransferase I (beta4GalT I) (E.C.2.4.1.38) causes a new congenital disorder of glycosylation (CDG), designated type IId (CDG-IId), a severe neurologic disease characterized by a hydrocephalus, myopathy, and blood-clotting defects. Analysis of oligosaccharides from serum transferrin by HPLC, mass spectrometry, and lectin binding revealed the loss of sialic acid and galactose residues. In skin fibroblasts and leukocytes, galactosyltransferase activity was reduced to 5% that of controls. In fibroblasts, a truncated polypeptide was detected that was about 12 kDa smaller in size than wild-type beta4GalT I and that failed to localize to the Golgi apparatus. Sequencing of the beta4GalT I cDNA and gene revealed an insertion of a single nucleotide (1031-1032insC) leading to premature translation stop and loss of the C-terminal 50 amino acids of the enzyme. The patient was homozygous and his parents heterozygous for this mutation. Expression of a corresponding mutant cDNA in COS-7 cells led to the synthesis of a truncated, inactive polypeptide, which localized to the endoplasmic reticulum.


Subject(s)
Congenital Disorders of Glycosylation/enzymology , Glycoproteins/blood , Transferrin/analysis , Uridine Diphosphate Galactose/deficiency , beta-N-Acetylglucosaminylglycopeptide beta-1,4-Galactosyltransferase/deficiency , Cells, Cultured , Child, Preschool , Chromatography, Affinity , Congenital Disorders of Glycosylation/etiology , Congenital Disorders of Glycosylation/metabolism , Fibroblasts/cytology , Fibroblasts/enzymology , Galactose/metabolism , Golgi Apparatus/metabolism , Humans , Immunohistochemistry , Infant , Leukocytes/enzymology , Male , Protein Transport/physiology , Skin/cytology , Skin/metabolism , Uridine Diphosphate Galactose/metabolism , beta-N-Acetylglucosaminylglycopeptide beta-1,4-Galactosyltransferase/genetics , beta-N-Acetylglucosaminylglycopeptide beta-1,4-Galactosyltransferase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...